Cargando…
Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
Alopecia areata (AA) is an autoimmune condition that causes patchy hair loss, affecting up to 147 million people globally. Currently, there are no treatments approved by US Food and Drug Administration (FDA) specific for AA, and there are few effective therapeutic options for widespread and persiste...
Autores principales: | Ramírez-Marín, Hassiel Aurelio, Tosti, Antonella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860347/ https://www.ncbi.nlm.nih.gov/pubmed/35210753 http://dx.doi.org/10.2147/DDDT.S334727 |
Ejemplares similares
-
Which is the Ideal JAK Inhibitor for Alopecia Areata – Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
por: Sardana, Kabir, et al.
Publicado: (2023) -
Role of Oral Minoxidil in Patterned Hair Loss
por: Ramírez-Marín, Hassiel Aurelio, et al.
Publicado: (2022) -
Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial
por: King, Brett, et al.
Publicado: (2022) -
Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
por: Thaçi, Diamant, et al.
Publicado: (2023) -
Characterizing the relationships between patient‐reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib
por: Winnette, R., et al.
Publicado: (2022)